Cost-effectiveness of adolescent pertussis vaccination for the netherlands: Using an individual-based dynamic model

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  de Vries, Robin ^a   Kretzschmar, Mirjam ^b,c   Schellekens, Joop F P ^d   Versteegh, Florens G A ^e   Westra, Tjalke A ^a   Roord, John J ^f   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Laboratory for Infectious Diseases   (Netherlands)

^e GROENE HART HOSPITAL   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PERTUSSIS VACCINE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HOSPITALIZATION; INCIDENCE; NETHERLANDS; OUTCOME ASSESSMENT; PERTUSSIS; PREDICTION; PROBABILITY; PROCESS MODEL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; ADOLESCENT; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; ECONOMICS; HUMAN; STATISTICAL MODEL; STATISTICS;

ADOLESCENT; COST-BENEFIT ANALYSIS; HUMANS; INCIDENCE; MODELS, ECONOMETRIC; NETHERLANDS; PERTUSSIS VACCINE; QUALITY-ADJUSTED LIFE YEARS; STOCHASTIC PROCESSES; WHOOPING COUGH;

EID: 78149424435     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013392     Document Type: Article

References (78)

1. Tan T, Trindade E, Skowronski D (2005) Epidemiology of Pertussis. Pediatr Infect Dis J 24: S10-18.
2. De Melker HE, Conyn-van Spaendonck MAE, Rümke HC, van Wijngaarden JK, Mooi FR, et al. (1997) Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg Infect Dis 3: 175-178.
3. De Melker HE, Schellekens JFP, Neppelenbroek SE, Mooi FR, Rümke HC, Conyn-van Spaendonck MAE (2000) Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis 6: 348-357.
4. Neppelenbroek SE, De Melker HE, Schellekens JFP, Conyn-van Spaendonck MAE (1999) The incidence of pertussis in the Netherlands remains high since an outbreak occurred in 1996. Euro Surveill 4: 133-134.
5. Schellekens JFP, Wirsing von König CH, Gardner P (2005) Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J 24: S19-24.
6. Kowalzik F, Barbosa AP, Fernandes VR, Carvalho PR, Avila-Aguero, et al. (2007) Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J 26: 238-242.
7. Orenstein WA (1999) Pertussis in adults: epidemiology, signs, symptoms, and implications for vaccination. Clin Infect Dis 28(Suppl 2): S147-150.
8. Rothstein E, Edwards K (2005) Health burden of pertussis in adolescents and adults. Pediatr Infect Dis J 24: S44-47.
9. Lee GM, Lett S, Schauer S, LeBaron C, Murphy TV, et al. (2004) Societal costs and morbidity of pertussis in adolscents and adults. CID 39: 1572-1580.
10. De Serres G, Shadmani R, Duval B, Boulianne N, Déry P, et al. (2000) Morbidity of pertussis in adolescents and adults. J Infect Dis 182: 174-179.
11. Van Amersfoorth SCM, Schouls LM, van der Heide HGJ, Advani A, Hallander HO, et al. (2005) Analysis of Bordetella pertussis populations in European countries with different vaccination policies. JCM 43: 2837-2843.
12. Dutch national immunization program (RVP). http://www.nvi-vaccin.nl/?id=564. Accessed 2008 May 1.
13. Wendelboe AM, Van Rie A, Salmaso S, Englund JA (2005) Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 24: S58-61.
14. Versteegh FGA, Schellekens JFP, Nagelkerke AF, Roord JJ (2002) Laboratoryconfirmed reinfections with Bordetella pertussis. Acta Paediatr 91: 95-97.
15. Fine PE (1993) Herd immunity: history, theory, practice. Epidemiol Rev 15: 265-302.
16. Halperin SA (2005) Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States. Pediatr Infect Dis J 24: S141-146.
17. Caro JJ (2005) Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 23: 323-332.
18. Hollingworth W, Spackman DE (2007) Emerging methods in economic modeling of imaging costs and outcomes: a short report on discrete event simulation. Acad Radiol 14: 406-410.
19. Karnon J (2003) Alternative decision modeling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Economics 12: 837-848.
20. Anderson RM, May RM (1991) Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press.
21. Kelton WD, Sadowski RP, Sadowski DA (2004) Simulation with ARENA. New York: McGraw-Hill.
22. De Melker HE, Conyn-van Spaendonck MAE, Schellekens JFP (1997) The pertussis epidemic in 1996: description and evaluation based on surveillance data from 1976 to 1996. Report no. 128507005, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
23. Van Boven M, de Melker HE, Schellekens JFP, Kretzschmar M (2000) Waning immunity and sub-clinical infection in an epidemic model: implications for pertussis in The Netherlands. Math Biosciences 164: 161-182.
24. Farrington CP (1992) The measurement and interpretation of age-specific vaccine efficacy. Int J Epidemiol 21: 1014-1020.
25. Ramsay MEB, Farrington CP, Miller E (1993) Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods. Epidemiol Infect 111: 41-48.
26. Health Council of the Netherlands (2004) Vaccination against Pertussis. Publication # 2004/04E. Den Haag: Health Council of the Netherlands.
27. Jefferson T, Rudin M, DiPietrantonj (2003) Systematic review of the effects of pertussis vaccines in children. Vaccine 21: 2012-2023.
28. Zhang L, Prietsch SOM, Axelsson I, Halperin SA (2010) Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev 1: CD001478.
29. Ward J, Cherry DJ, Chang SJ, Partridge S, Lee H, et al. (2005) Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 353: 1555-1563.
30. Frampton JE, Keam S (2006) Reduced-antigen, combined diphtheria-tetanusacellular pertussis vaccine, adsorbed (Boosterix® US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years. Pediatr Drugs 8: 189-195.
31. Casey JR, Pichichero ME (2005) Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. Drugs 65: 1367-1389.
32. De Greeff SC, Schellekens JFP, Mooi FR, de Melker HE (2003) Pertussis in the Netherlands, 2001-2002. RIVM report 128507010.
33. De Melker HE, Versteegh FGA, Schellekens JFP, Teunis PFM, Kretzschmar M (2006) The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. Journal of Infection 53: 106-113.
34. Wallinga J, Teunis P, Kretzschmar M (2006) Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. Am J Epidemiol 164: 936-944.
35. Mylius SD, Hagenaars TJ, Lugnér AK, Wallinga J (2008) Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine 26: 3742-3749.
36. The World Bank. Available http://www.world-bank.org. Accessed 2008 September 01.
37. Health Care Insurance Board. Dutch Guidelines for Pharmacotherapeutics. Diemen, The Netherlands, 2008. Available: http://www.fk.cvz.nl. Accessed 2008 September 01.
38. Prismant: National LMR information [online and further data requested]. Available: http://www.prismant.nl.
39. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH (2004) Guideline for costing research, methods and standardized prices for economic evaluations in health care. Diemen: Health Care Insurance Board.
40. Tormans G, van Doorslaer E, van Damme P, Clara R, Schmitt HJ (1998) Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany. Eur J Pediatr 157: 395-401.
41. Lee LH, Pichichero ME (2000) Costs of illness due to Bordetella pertussis in families. Arch Fam Med 9: 989-996.
42. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 3th edition.
43. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L (1995) The friction cost method for measuring indirect costs of disease. J Health Econ 14: 171-189.
44. Statistics Netherlands. Available: http://stadline.cbs.nl. Accessed 2008 September 01.
45. Lee GM, Salomon JA, LeBaron CW, Lieu TA (2005) Health-state valuations for pertussis: methods for valuing short-term health states. Health and Quality of Life Outcomes 3: 17-30.
46. Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, Schauer S, et al. (2007) Cost-effectiveness of pertussis vaccination in adults. Am J Prev Med 32: 186-193.
47. Dutch guidelines for pharmacoeconomic research. Health Care Insurance Board 2006. Available: http://www.ispor.org/PEguidelines/source/PEguidelinesenglish.pdf.
48. Riteco JA, De Heij LJM, van Luijn JCF, Wolff I (1999) Guidelines for pharmacoeconomic research. Amstelveen: College voor Zorgverzekeringen.
49. Caro JJ, Getsios D, El-Hadi W, Payne K, O'Brien JA (2005) Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J 24: S75-82.
50. Calugar A, Ortega-Sánchez IR, Tiwari T, Oakes L, Jahre JA, et al. (2006) Nosocomial pertussis: costs of an outbreak and benefits of vaccinating health care workers. CID 42: 981-988.
51. Iskedjian M, Einarson TR, O'Brien BJ, de Serres G, Gold R, et al. (2001) Economic evaluation of a new acellular vaccine for pertussis in Canada. Pharmacoeconomics 19: 551-563.
52. Scuffham PA, McIntyre PB (2004) Pertussis vaccination strategies for neonates: an exploratory cost-effectiveness analysis. Vaccine 22: 2953-2964.
53. Koplan JP, Schoenbaum SC, Weinstein MC, Fraser DW (1979) Pertussis vaccine: an analysis of benefits, risks and costs. N Engl J Med 301: 906-911.
54. Hinman AR, Koplan JP (1984) Pertussis and pertussis vaccine: reanalysis of benefits, risks and costs. JAMA 251: 3109-3113.
55. Hinman AR, Koplan JP (1985) Pertussis and pertussis vaccine: further analysis of benefits, risks and costs. Develop Biol Standard 61: 429-437.
56. Lee GM, Riffelmann M, Wirsing von Konig CH (2008) Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine 26: 3673-3679.
57. Beutels P, Bonanni P, Tormans G, Canale F, Crovari PC (1999) An economic evaluation of universal pertussis vaccination in Italy. Vaccine 17: 2400-2409.
58. Ekwueme DU, Strebel PM, Hadler SC, Meltzer MI, Allen JW, et al. (2000) Economic evaluation of use of Diphtheria, tetanus and, acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. Arch Pediatr Adolesc Med 154: 797-803.
59. Iskedjian M, Walker JH, Hemels MEH (2004) Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine 22: 4215-4227.
60. Iskedjian M, Walker JH, de Serres G, Einarson TR (2005) Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada. Pediatr Drugs 7: 123-136.
61. Purdy KW, Hay JW, Botteman MF, Ward JI (2004) Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. CID 39: 20-28.
62. Stevenson M, Beard S, Finn A, Brennan A (2002) Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination schedule. Vaccine 20: 1778-1786.
63. Edmunds JE, Medley GF, Nokes DJ (1999) Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Statist Med 18: 3263-3283.
64. Van Boven M, de Melker HE, Schellekens JFP, Kretzschmar M (2001) A model based evaluation of the 1996-7 pertussis epidemic in the Netherlands. Epidemiol Infect 127: 73-85.
65. Hethcote HW (1997) An age-structured model for pertussis transmission. Math Biosciences 145: 89-136.
66. Hethcote HW (1999) Simulations of pertussis epidemiology in the United States: effects of adult booster vaccinations. Math Biosciences 158: 47-73.
67. Hethcote HW, Horby P, McIntyre P (2004) Using computer simulations to compare pertussis vaccination strategies in Australia. Vaccine 22: 2181-2191.
68. Van Rie A, Hethcote HW (2004) Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 22: 3154-3165.
69. Coudeville L, van Rie A, Andre P (2008) Adult pertussis vaccination strategies and their impact on pertussis in the United States: evaluation of routine and targeted (cocoon) strategies. Epidemiol Infect 136: 604-620.
70. Edmunds WJ, Brisson M, Melegaro A, Gay NJ (2002) The potential costeffectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 20: 1316-1330.
71. Grenfell BT, Anderson RM (1985) The estimation of age-related rates of infection from case notifications and serological data. J Hygiene 95: 419-436.
72. Brisson M, Edmunds WJ (2003) Economic evaluation of vaccination programmes: the impact of herd-immunity. Med Decis Making 23: 76-82.
73. Lee GM, LeBaron C, Murphy TV, Lett S, Schauer S, et al. (2005) Pertussis in adolescents and adults: should we vaccinate? Pediatrics 115: 1675-1684.
74. Van Amersfoorth SCM, Schouls LM, van der Heide HGJ, Advani A, Hallander HO, et al. (2005) Analysis of Bordetella pertussis populations in European countries with different vaccination schemes. J Clin Microbiol 43: 2 837-2843.
75. Crowcroft NS, Andrews N, Rooney C, Brisson M, Miller E (2002) Deaths from pertussis are underestimated in England. Arch Dis Child 86: 336-338.
76. Shaikh R, Guris D, Strebel PM, Wharton M (1998) Underreporting of pertussis deaths in the United States: need for improved surveillance. Pediatrics 101: 323.
77. Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, et al. (2006) Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics 117: 1084-1093.
78. Bos JM, Postma MJ. Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness? Exp Rev Pharmacoeconom Res 2004;4: 247-50.